We have used the technique of in vitro selection to generate variants of human immunodeficiency virus type 1 (H1V-i) that are resistant to 2',3'-dideoxyinosine (ddl) and cross-resistant to 2',3'-dideoxycytidine (ddC ATG --GTG) and 294 (Pro --Ser; CCA -* TCA). These mutations were introduced in the pol gene of infectious, cloned HXB2-D DNA by site-directed mutagenesis. Viral replication assays confirmed the importance of site 184 with regard to resistance to ddl. The recombinant viruses thus generated displayed more than fivefold-greater resistance to ddl than parental HXB2-D did. Moreover, more than fivefold-greater resistance to ddC was also documented; however, the recombinant viruses continued to be inhibited by zidovudine (AZT). No resistance to ddI, ddC, or AZT was introduced by inclusion of mutation site 294 in the pol gene of HXB2-D. PCR analysis performed on viral samples obtained from patients receiving long-term ddl therapy confirmed the presence of mutation site 184 in five of seven cases tested. In three of these five positive cases, the wild-type codon was also detected, indicating that mixtures of viral quasispecies were apparently present. Viruses possessing a ddI resistance phenotype were isolated from both subjects whose viruses contained only the mutated rather than wild-type codon at position 184 as well as from a third individual, whose viruses appeared to be mostly of the mutated variety.
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Resistance to nucleoside antiretroviral compounds has been reported to occur among isolates of human immunodeficiency virus type 1 (HIV-1) from patients receiving prolonged therapy with these drugs (10, 17, 27, 31) . In addition, some investigators have reported that drug-resistant HIV variants can be amplified in vitro by gradually increasing the concentrations of these drugs in tissue culture medium (12, 16) . Generation of HIV resistance to nonnucleoside antagonists of viral reverse transcriptase (RT) has also been demonstrated through in vitro selection procedures (23, 25) . 3'-Azido-3'-deoxythymidine (zidovudine; AZT) and other antiretroviral drugs have been shown to impact positively on both quality of life and survival of HIV-1-infected individuals (8, (34) (35) (36) . Although many patients become intolerant of these drugs after prolonged therapy and suffer clinical deterioration (7, 21, 22) , the relationship between the appearance of drug-resistant viruses and clinical status is still unclear.
The RT of retroviruses is widely considered to be the target of antiretroviral agents which can act as chain terminators of proviral DNA synthesis (11) . The RT of HIV-1 displays considerable infidelity during the replication of viral RNA (24, 26, 32) . Unsurprisingly, a number of mutations have been found in the pol genes of HIV-1 variants that display resistance to AZT (18), 2',3'-dideoxyinosine (ddI) (31) , and 2',3'-dideoxycytidine (ddC) (10) . It has been shown that a mutation at site 74 in the RT- (12) were studied extensively. In addition, we employed the HXB2-D clone of full-length infectious DNA (9) . A concentration of 40 ,uM ddI (Bristol-Myers Squibb, Wallingford, Conn.) was utilized for routine propagation of viruses possessing a ddI resistance phenotype. This is approximately 10-fold the usual 50% inhibitory concentration (IC50) for ddI-sensitive viral strains.
In some experiments, viruses that had initially been grown on MT-4 cells were passaged onto phytohemagglutininprestimulated cord blood lymphocytes (CBL) obtained from the Department of Obstetrics of our hospital, as described previously (28) . For subsequent analysis, samples of CBL (5 x 105 cells per ml) were pretreated with various concentrations of ddl ranging between 0 p,M and 200 ,uM for 4 h and were then inoculated with CBL-grown HIV-1 at a multiplicity of infection of 1.0 (as determined by plaque assay on MT-4 cells) (12) in the concentration of ddl used for pretreatment. Fresh medium, including the appropriate concentration of ddI, was added three times weekly, and fresh phytohemagglutinin-prestimulated CBL (5 x 105 cells per ml) were added at 2-day intervals. Similar studies were performed with ddC or AZT at concentrations of between 0 and 10 p,M.
Oligonucleotides. The construction of HXB2-D used in these studies is shown in Fig. 1 . All of the oligonucleotides used in this work were mapped as shown in Fig. 2 primers used to discriminate wild-type from mutated sequences at the Val-184 codon in the RT-coding region of HIV-1. 184mG and 294mT were used only in site-directed mutagenesis experiments (see below).
Cloning and sequencing of the RT region. Total cellular DNA was extracted from about 2 x 106 MT-4 cells that had been infected with a ddI-resistant isolate of HIV-1 initially derived from HIV-IIIB by tissue culture passage selection (12) . The cells were harvested and washed twice with phosphate-buffered saline. They were then lysed with 0.5 ml of 0.5% sodium dodecyl sulfate-Tris-EDTA (pH 8.0) buffer, digested with 20 ,ug of pronase per ml for 5 h at 37°C, and then phenol extracted. A 1,742-bp segment containing the complete RT-coding sequence plus 34 bases of the 3' end of the protease-coding sequence and 28 bases of the 5' end of the integrase-coding sequence was amplified by polymerase chain reaction (PCR) (29) by using the RT01 and RT02 primers for the 5' and 3' ends, respectively. About 0.5 ,ug (5 pJ of extract) of extracted cellular DNA was initially used for each PCR mix (total of 100 pAl), which contained 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 0.01% (wt/vol) gelatin, 2.5 U of Taq polymerase, a 0.2 mM concentration of each deoxynucleoside triphosphate (Pharmacia Fine Chemicals, Montreal, Quebec, Canada), and 0.4 ,uM each RT01 and RT02. Samples were overlaid with 100 ,ul of light mineral oil and heated to 94°C for 5 min before being subjected to 35 thermal cycles of 1 min at 94°C for denaturing, 2 min at 55°C Thus, MT-4 cells were infected with clinical isolates, and total cellular DNA was extracted. Concentrations of PCR primers utilized in each reaction mix were as follows: 184U, 1.2 ,uM; 184G and 184W, 0.65 ,uM; and 184D, 0.5 ,uM. The samples were subjected to 35 thermal cycles of 40 s at 94°C for denaturing, 20 s at 53°C for annealing, and 30 s at 72°C for extension. The PCR products were separated through 2% agarose. Other procedures were performed as described above.
In addition, we performed PCR analysis for detection of the previously described site 41 mutation (Met --Leu)
conferring resistance to AZT (14) . fragment of pHIVpol thus generated was replaced by the mutated fragment from mpHIVRT184 to produce pHIV poll84.
A 1.9-kb BalI fragment from pHIVpoll84 was substituted for the appropriate fragment of HXB2-D to produce HXB2-D184. E. coli TG1 cells were transformed with HXB2-D184 and screened by endonuclease digestion. The orientation of the cloned fragment was determined by PCR with the RT01 and RT02 primers shown in Fig. 2 . The Val-184 (ATA GTA) mutation was confirmed by DNA sequencing.
A recombinant virus, HXB2D-294, containing a CCA -TCA substitution at codon 294 (resulting in replacement of proline by serine) was constructed in the same manner as described above for HXB2D-184, except that oligonucleotide 294mT was used instead of 184mG. In some experiments, a recombinant that contained the substitutions mentioned above at positions 184 and 294 (HXB2-D184+294) was constructed. For purposes of such construction, an oligonucleotide/template ratio of 40:1 was used instead of the 22:1 ratio that was used for single-codon substitutions.
Transfection and preparation of virus stock. MT-4 cells (5 x 106) were harvested, washed twice with cold RPMI 1640 medium containing 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 ,ug/ml), resuspended in 0.8 ml of cold supplemented RPMI 1640 medium, and mixed with 20 ,ug of DNA. After standing on ice for 10 min, the cells were transfected by electroporation at 250 V and 960 ,uF (6) with a Bio-Rad Gene Pulser. The electroporated cells were kept on ice for 10 min and then washed with cold supplemented RPMI 1640 medium. The transfected cells were resuspended in 10 ml of RPMI 1640 medium containing 20% FBS plus antibiotics and incubated at 37°C under 5% CO2. To generate virus stock, fresh MT-4 cells were added to expand the culture after cytopathic effects were observed, and the cultures were maintained for 2 to 3 days. Culture supernatants were harvested and frozen in aliquots at -700C prior to use.
Assays of viral replication and drug sensitivity. Assays of HIV-1 susceptibility to drugs, RT assays, and indirect immunofluorescence assays for detection of p24 were performed as previously described (3, 28) . Antigen capture tests for occasional and confirmatory determination of p24 levels in culture fluids were carried out with kits purchased for this purpose from Abbott Laboratories (North Chicago, Ill.). Isolation of virus from patients was performed with CBL in the absence of drug, as described elsewhere (12) . After amplification of virus by further replication in CBL in the absence of drug, studies examined the ability of such isolates to replicate when the drug was present at a variety of concentrations. This permitted the calculation of IC50 determinations on the basis of RT levels in culture fluids, as previously described (12) .
RESULTS
To determine the oligonucleotide mutations responsible for HIV-1 resistance to ddl, we have cloned and sequenced the complete RT-coding region of a number of ddI-resistant variants of HIV-IIIB selected in vitro (12) . The results of such studies showed that several such viruses apparently contained mutations in the RT-coding region at codons 184 (Met --Val; ATG -* GTG) and 294 (Pro -) Ser; CCA --TCA) in comparison with parental drug-sensitive HIV-IIIB.
To confirm the biological significance of these mutations, we used site-directed mutagenesis to introduce the valineencoding triplet GTG into position 184 and the serineencoding TCA into position 294 of the HIV-1 RT gene of the infectious molecular clone HXB2-D, yielding the mutant clones HXB2-D184 and HXB2-D294. In addition, we generated a construct, HXB2-D184+294, containing both of these changes. The susceptibilities of HXB2-D184, HXB2-D294, HXB2-D184+294, and wild-type HXB2-D to ddI and other drugs were assessed by viral replication in MT-4 cells; IC50s were calculated from levels of RT activity in culture fluids. Figure 3 presents data demonstrating the abilities of parental HXB2-D and HXB2-D184 to replicate in the presence of different concentrations of ddI, ddC, and AZT. It is apparent that the presence of the GTG substitution at position 184 caused a significant diminution in susceptibility to both ddl (Fig. 3a) and ddC (Fig. 3b) . However, little or no resistance to AZT was seen when concentrations approaching the usual IC50s of this drug, e.g. 0.05 R,M, were used (Fig. 3c) .
These findings are summarized in Table 2 , which shows that the Val-184 mutation caused more than a fivefold decrease in susceptibility to ddI and ddC but did not affect sensitivity to AZT. However, the substitution of serine for proline at position 294 did not affect drug susceptibility (Table 2 ). In addition, the combination of both of these mutations, yielding HXB2-D184+294, did not give rise to a level of drug resistance higher than that seen with the mutation at codon 184 alone. Similar observations were obtained on the basis of assays for detection of p24 antigen in culture fluids and indirect immunofluorescence assays for p24 antigen in infected cells (data not shown).
To distinguish the wild-type codon from the mutated codon at RT position 184, we employed specific primer pairs and PCR as described in Materials and Methods. Viruses which were isolated from the peripheral blood mononuclear cells of HIV-infected patients receiving prolonged (>6 months) ddI therapy were grown in MT-4 cells in the continuous presence of ddI (40 ,M) for 3 days, after which cellular DNA was extracted for purposes of PCR amplification. Similar analyses were performed as controls with ddl-resistant viruses generated in tissue culture through selection pressure as well as with wild-type control viruses derived from patients or grown in culture in the absence of drug. In these studies, we The results in Fig. 4 show that, as expected, no viral DNA could be detected in uninfected (lanes A and B) with virus from patient 1552, who had been treated with ddI for 14 months, with the mutated form only being present (lanes D and J). Patient 1559, who had been treated with ddI for 11 months, yielded virus that was apparently heterogeneous for mutation 184, with both wild-type and mutated forms being present (lanes E and K); however, the mutated form appeared to be predominant. In contrast, viruses derived from subjects 1266 and 1241, who had been treated with ddl for 4 and 5 months, respectively, contained only the wild-type form of codon 184 (lanes F and G, respectively), with no apparent presence of mutated sequences (lanes L and M, respectively). Table 3 summarizes the therapeutic regimens received by the patients studied as well as the detection of resistanceconferring mutation sites as determined by PCR analysis. All subjects had been monitored off protocol, and had received AZT for various times before being switched to ddl therapy for reasons of AZT intolerance. Most of these individuals were still asymptomatic, although a few had progressed to mild forms of lymphadenopathy. Pretreatment isolates from these individuals were not available. Nonetheless, the results in Table 3 show that viruses isolated from patients receiving prolonged ddI therapy were resistant to this compound in some cases, as determined in tissue culture. Although pretreatment isolates from the same individuals were not available for comparison, the ranges of IC50s obtained for most of the isolates are consistent with previous reports describing a drug-sensitive phenotype (12, 31) . In contrast, patients 1051, 1552, and 1559 possessed viruses for which the IC50s of ddI were 4 to 10 times higher than those commonly seen. On this basis and because ddI-resistant isolates generally require IC50s approximately fivefold higher than those required by paired pretreatment isolates (31) , these viruses were considered to be resistant to ddI. In order to possibly shed light on the relationship between the mutation at site 41, which confers resistance to AZT (since all patients had been treated with this drug), and the mutation at site 184, we also performed PCR analysis to detect the former codon change, as described in Materials and Methods. Only two individuals studied (patients 1051 and 1266) showed evidence of the site 41 mutation (Table 3) .
Finally, we wished to determine whether the site 184 mutation would persist after replication of ddI-resistant HIV-1 in CBL. Accordingly, both wild-type HXB2-D and HXB2-D184 were grown for 2 weeks in CBL in the absence of drug pressure, as described in Materials and Methods. Cloning and sequencing showed that HXB2-D continued to possess a wild-type ATG (Met) codon at position 184 after this time, while HXB2-D retained the GTG (Val) mutation described above. IC50 determinations performed on the basis of RT levels in culture fluids, after replication in CBL at a variety of drug concentrations, showed that the site 184 mutation continued to account for resistance to both ddl and ddC (Table 4) .
DISCUSSION
The development of HIV-1 resistance to antiretroviral drugs may become an important problem in the therapy of HIV-1-infected individuals (10, 20, 30) . This may be attributable to the infidelity of HIV-1 RT, which leads to mutagenesis during reverse transcription; hence, mutations conferring resistance to antiviral drugs might easily emerge under conditions of drug pressure. Indeed, multiple mutations in the RT-coding regions of AZT-resistant variants of HIV-1 have been demonstrated. The biological relevance of these mutations has been confirmed by site-directed mutagenesis, and combinations of certain mutations have been shown to yield higher degrees of resistance than single mutations (18) . In addition, a single-amino-acid substitution has been reported for resistance to ddI and cross-resistance to ddC (10, 31) . Interestingly, the presence of this Val-74 mutation in the RT of ddI-resistant HIV-1, isolated from patients who had previously received prolonged AZT therapy and who possessed AZT-resistant virus in their blood, caused an apparent increase in sensitivity to AZT (31) . This paper reports a novel mutation at codon 184 (Met Val) associated with HIV-1 resistance to ddI and crossresistance to ddC. This work grew out of cloning and sequencing studies performed with the complete RT-coding region of a HIV-IIIB derivative previously shown to be resistant to ddI. We identified two mutations at codons 184 (ATG --GTG) and 294 (CCA --TCA) as potentially responsible for the observed resistance. Amino acid 184 is located in a highly conserved region of the RT (1, 2, 13, 20, 33) , in which the sequence consisting of amino acids 183 to 186 has been reported to be crucial to RT enzymatic function (4, 19, 20) . Single mutations at position 184, introduced by site-directed mutagenesis, caused reductions in RT activity of 80% in the case of Met --Tyr and 95% in the case of Met Leu (4, 19) . In our studies, a change from the hydrophobic amino acid methionine at this site to the aliphatic amino acid valine led to resistance to both ddI and ddC. This cross-resistance may be due to the fact that both ddI and ddC possess 2',3'-dideoxy moieties. We have also found the Val-184 substitution in variants of HIV-1 that have been selected in vitro for resistance to ddC (not shown). Our failure to demonstrate cross-resistance to AZT may be due to the 3'-azido moiety of the AZT molecule. It is consistent as well that the Val-184 substitution is not present in variants of HIV-1 selected for resistance to AZT (12) . As mentioned above, a mutation at Val-74 is also associated with cross-resistance to both ddI and ddC (31) . Interestingly, a mutation at site 181 that causes a Tyr-to-Cys alteration in the RT primary structure is apparently responsible for the generation of resistance to nonnucleoside inhibitors of viral RT that act by noncompetitive inhibition (22, 25) . The fact that we were unable to confirm the biological significance of the mutation at site 294 indicates the necessity to perform site-directed mutagenesis in this work.
Our previous report on a ddI-resistant derivative of HIV-I"B generated through in vitro selection showed that this virus required an IC50 over 20-fold higher than that required by the parental virus and was not resistant to ddC (12 The two individuals whose isolates lacked the site 184 mutation had received ddl therapy for less than 6 months. Of the five individuals positive for mutation 184, three also possessed the wild-type codon for this site, indicating that mixtures of viruses were present. This finding is consistent with previous observations of mixtures of viral quasispecies that showed heterogeneity for mutation sites relevant to AZT. Interestingly, our study showed that those individuals in whom virus with the site 184 mutation was present to the greatest extent were also the donors from whom ddI-resistant viruses were most easily isolated. This indicates that the site 184 mutation is likely to occur in at least some patients who develop ddI-resistant variants of HIV-1.
The patients studied had received AZT for various periods before being switched to ddl. Therefore, we wanted to ascertain the relationship between mutation site 184 and the AZT resistance-conferring mutation at site 41 in terms of possible synergy with regard to resistance to ddM. No apparent relationship was shown to exist. Nonetheless, similar studies of the presence or absence of the other sites known to confer resistance to AZT are in order, as is work on possible synergy between sites 184 and 74 in the development of resistance to ddl.
